Contact Lenses Deliver Electrical Signals to Treat Depression in Mice
Researchers tested transparent contact lenses with built-in electrodes on mice for 30 minutes daily over three weeks. The treatment produced mood and behavior improvements comparable to fluoxetine, the active ingredient in Prozac.
New York PostA study published in Cell Reports Physical Science tested transparent contact lenses equipped with electrodes that deliver mild electrical signals to brain regions linked to mood. The method uses temporal interference, sending two electrical signals through the retina that intersect only at targeted deep brain areas.
Senior author Jang-Ung Park of Yonsei University said the approach is similar to two flashlights whose beams overlap to create a bright spot far from the source. Researchers compared four groups of mice: those receiving the lens treatment, those given fluoxetine, untreated depressed mice, and a non-depressed control group.
All measured signs of depression, including behavior, brain recordings, and biomarkers, decreased in the contact-lens group.
The lenses reduced inflammatory molecules in the brain, lowered blood corticosterone levels by 48 percent, and raised serotonin levels by 47 percent. Brain connectivity between the hippocampus and prefrontal cortex, which depression disrupts, was restored according to electrophysiological recordings.
A machine learning model grouped the contact-lens mice with the non-depressed control group based on behavior, brain activity, and biomarker data.
Park said the team plans to make the lenses fully wireless, test long-term safety in larger animals, and personalize stimulation before moving to human clinical trials. Researchers also stated the approach could be applied to anxiety, drug addiction, and cognitive decline.
Key Facts
Story Timeline
2 events- Study period
Mice received contact-lens treatment 30 minutes daily for three weeks.
1 sourceNew York Post - Publication
Findings appeared in Cell Reports Physical Science.
1 sourceNew York Post
Potential Impact
- 01
Further animal testing is required before human clinical trials can begin.
- 02
If successful in humans, the approach could offer a non-drug option for depression.
Transparency Panel
Related Stories
The GuardianWHO Chief Visits DRC as Ebola Death Rate Reaches 30-50%
World Health Organization director-general Tedros Adhanom Ghebreyesus arrived in the Democratic Republic of the Congo to support containment of a new Ebola outbreak. The agency revised the death rate to 30-50% based on confirmed cases and recorded 10 confirmed and 223 suspected d…
westernjournal.comGreek National Charged in UK With Aiding Iran-Linked Intelligence Service
A 46-year-old Greek man living in Germany was charged under the UK National Security Act with assisting an intelligence service believed to be Iran by targeting a journalist at Iran International.
straitstimes.comJournalists in Gaza to Receive 2026 Golden Pen of Freedom Award
Three international news agencies will accept the award on behalf of their local staff still reporting from the territory. The World Association of News Publishers cited the journalists' continued coverage under extreme conditions.